Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Control group:Conventional treatment
Sponsors
Hebei Province Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed COVID-19 by Pathogen testing; 2. Above 18 years old (inclusive); 3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, expectoration, chest tightness, polypnea, dyspnea); 4. Voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development; 2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation. Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis; 3. Severe pneumonia requires mechanical ventilation; 4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; 5. Pregnant or lactating women; 6. Patients who participated in other clinical trials within the last 3 months; 7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug; 8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms (fever, cough,expectoration,chest tightness, polypnea, dyspnea) recovery rate and recovery time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Single symptom disappearance rate and main symptom disappearance time;Changes in color, quality and quantity of sputum in patients with expectoration;Changes in oxygenation index (OI);Proportion of aggravation during treatment (in line with the definition of severe or critical illness in the treatment scheme);Rate of CT improvement;Disease recovery rate;Time and rate of coronavirus become negative; | — |
Countries
China
Contacts
Public ContactLiu Qingquan/Jiang Rongmeng/Yan Xixin/Mei Jianqiang/Wu Shucai
Hebei Province Chest Hospital
Outcome results
None listed